Sumitomo Pharma’s enzomenib receives FDA orphan drug designation for acute lymphoblastic leukemia
FDA orphan drug status expands enzomenib’s ALL pathway as Sumitomo Pharma advances pivotal development in biomarker-defined acute leukemia.
Pharma & Biotech